

Mathangi Gopalakrishnan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8561061/publications.pdf>

Version: 2024-02-01

40
papers

456
citations

840776

11
h-index

794594

19
g-index

42
all docs

42
docs citations

42
times ranked

597
citing authors

#	ARTICLE	IF	CITATIONS
1	Reassessing the Pediatric Dosing Recommendations for Unfractionated Heparin Using Real-World Data: A Pharmacokinetic-Pharmacodynamic Modeling Approach. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 733-746.	2.0	3
2	Interspecies Comparison and Radiation Effect on Pharmacokinetics of BIO 300, a Nanosuspension of Genistein, after Different Routes of Administration in Mice and Non-Human Primates. <i>Radiation Research</i> , 2022, 197, .	1.5	7
3	Development and Use of an Ex-Vivo In-Vivo Correlation to Predict Antiepileptic Drug Clearance in Patients Undergoing Continuous Renal Replacement Therapy. <i>Pharmaceutical Research</i> , 2022, , .	3.5	1
4	A New Zealand White rabbit model of thrombocytopenia and coagulopathy following total body irradiation across the dose range to induce the hematopoietic-subsyndrome of acute radiation syndrome. <i>International Journal of Radiation Biology</i> , 2021, 97, S19-S31.	1.8	7
5	Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration. <i>Psychiatric Research and Clinical Practice</i> , 2021, 3, 38-45.	2.4	1
6	Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	19
7	Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials. <i>Clinical Pharmacokinetics</i> , 2021, 60, 527-540.	3.5	19
8	A novel approach for personalized response model: deep learning with individual dropout feature ranking. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 165-179.	1.8	5
9	Model-Based Approach to Improve Clinical Outcomes in Neonates With Opioid Withdrawal Syndrome Using Real-World Data. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 243-252.	4.7	3
10	Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy. <i>Pharmacotherapy</i> , 2021, 41, 205-211.	2.6	8
11	Evaluation of Switch-Brand Rates as a Potential Signal for Therapeutic Equivalency of Generic Antidepressants: A Real-World Retrospective Cohort Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 443-451.	4.7	2
12	A prospective, real-world, clinical pharmacokinetic study to inform lacosamide dosing in critically ill patients undergoing continuous venovenous haemofiltration (PADREA02). <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4375-4385.	2.4	2
13	Evaluation of an ex-vivo neonatal extracorporeal membrane oxygenation circuit on antiepileptic drug sequestration. <i>Perfusion (United Kingdom)</i> , 2021, , 026765912110281.	1.0	0
14	Analysis Approaches to Identify Pharmacogenetic Associations With Pharmacodynamics. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 589-594.	4.7	9
15	An Innovative Disease-Drug-Trial Framework to Guide Binge Eating Disorder Drug Development: A Case Study for Topiramate. <i>Clinical and Translational Science</i> , 2020, 13, 88-97.	3.1	5
16	Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications. <i>JAMA Psychiatry</i> , 2020, 77, 1064.	11.0	11
17	A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	16
18	Response to racial association and pharmacotherapy in neonatal opioid withdrawal syndrome: thinking beyond genetics. <i>Journal of Perinatology</i> , 2020, 40, 691-692.	2.0	1

#	ARTICLE	IF	CITATIONS
19	Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock. <i>Pharmacotherapy</i> , 2020, 40, 211-220.	2.6	9
20	Assessment of Similarity in Antipsychotic Exposureâ€Response Relationships in Clinical Trials Between Adults and Adolescents With Acute Exacerbation of Schizophrenia. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 848-859.	2.0	5
21	Manufacturing biological medicines on demand: Safety and efficacy of granulocyte colonyâ€stimulating factor in a mouse model of total body irradiation. <i>Biotechnology Progress</i> , 2020, 36, e2970.	2.6	6
22	A Practiceâ€Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADREâ€01). <i>Clinical and Translational Science</i> , 2020, 13, 950-959.	3.1	8
23	The Trend of Increasing Placebo Response and Decreasing Treatment Effect in Schizophrenia Trials Continues. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	20
24	Racial association and pharmacotherapy in neonatal opioid withdrawal syndrome. <i>Journal of Perinatology</i> , 2019, 39, 1370-1376.	2.0	16
25	A Quantitative Justification of Similarity in Placebo Response Between Adults and Adolescents With Acute Exacerbation of Schizophrenia in Clinical Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1046-1055.	4.7	6
26	450. Evaluation of Linezolid Pharmacokinetics in Obese Patients with Severe Skin and Soft-Tissue Infections. <i>Open Forum Infectious Diseases</i> , 2019, 6, S221-S221.	0.9	0
27	Population pharmacokinetics and exposureâ€response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 319-328.	2.3	9
28	Development and validation of a HPLCâ€UV assay for quantification of levetiracetam concentrations in critically ill patients undergoing continuous renal replacement therapy. <i>Biomedical Chromatography</i> , 2018, 32, e4257.	1.7	6
29	Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (GlaritusÂ®) and LantusÂ® in healthy subjects: a double-blind, randomized clamp study. <i>Acta Diabetologica</i> , 2018, 55, 461-468.	2.5	11
30	Lacosamide Pharmacokinetics in a Critically Ill Patient Receiving Continuous Venovenous Hemofiltration. <i>Pharmacotherapy</i> , 2018, 38, e17-e21.	2.6	12
31	Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1688-1700.	2.4	7
32	Exposureâ€response analysis after subcutaneous administration of RBPâ€7000, a onceâ€aâ€month longâ€acting Atrigel formulation of risperidone. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1476-1498.	2.4	18
33	Parentâ€Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABTâ€888), a PARP Inhibitor, in Patients With <i>BRCA 1/2</i> Mutated Cancer or PARPâ€Sensitive Tumor Types. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 977-987.	2.0	17
34	Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation. <i>Pharmaceutical Statistics</i> , 2017, 16, 232-249.	1.3	58
35	Bayesian Forecasting Tool to Predict the Need for Antidote in Acute Acetaminophen Overdose. <i>Pharmacotherapy</i> , 2017, 37, 916-926.	2.6	7
36	Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers. <i>Clinical Drug Investigation</i> , 2017, 37, 937-946.	2.2	16

#	ARTICLE	IF	CITATIONS
37	Exposureâ€Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies. <i>Clinical Cancer Research</i> , 2017, 23, 6421-6429.	7.0	4
38	Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 247-254.	2.0	5
39	Levonorgestrel release rates over 5 years with the Liletta® 52-mg intrauterine system. <i>Contraception</i> , 2016, 94, 353-356.	1.5	29
40	Pharmacokinetic Studies of Florfenicol in Koi Carp and Threespot Gourami <i>Trichogaster trichopterus</i> after Oral and Intramuscular Treatment. <i>Journal of Aquatic Animal Health</i> , 2005, 17, 129-137.	1.4	68